Beneficial ownership transparency
Beneficial ownership transparency in Healthcare & Life Sciences is no longer a peripheral compliance concern. The U.S. Financial Crimes Enforcement Network's Corporate Transparency Act reporting rules, now in active enforcement following the January 2024 compliance deadline for existing entities, directly reach healthcare holding structures, private equity-backed provider groups, and life sciences portfolio companies with layered ownership arrangements. The U.S. Department of Health and Human Services Office of Inspector General and the U.S. Securities and Exchange Commission have each signaled that opacity in ownership chains is a fraud and disclosure risk, not just an AML formality.
Watch
- FinCEN Beneficial Ownership Information rule: exemption scope for large operating companies in healthcare
- OIG advisory opinions touching indirect ownership disclosure in joint venture arrangements
- State-level Medicaid ownership reporting thresholds diverging from federal CTA definitions
- SEC scrutiny of 13D/G filings where life sciences acquirers use layered fund structures
- CTA willful non-compliance penalties reaching $591 per day for unreported entities
Recent material activity in Healthcare & Life Sciences
Active monitoring in place across Healthcare & Life Sciences. Material developments related to beneficial ownership transparency will appear here as they are published.